Goldman Sachs Discloses Passive Stake in Ligand Pharma
Ticker: LGNZZ · Form: SC 13G · Filed: Feb 12, 2024 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | SC 13G |
| Filed Date | Feb 12, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharma, SC-13G
TL;DR
**Goldman Sachs just revealed a big, passive stake in Ligand Pharma, signaling institutional confidence.**
AI Summary
Goldman Sachs Group Inc. filed an SC 13G on February 12, 2024, disclosing that as of December 29, 2023, they hold a significant stake in Ligand Pharmaceuticals Inc. This filing indicates Goldman Sachs's position as a passive investor, holding common stock with a par value of $0.001 per share. This matters to investors because it signals a major financial institution's confidence in Ligand Pharmaceuticals, potentially influencing market perception and stock stability.
Why It Matters
A major institutional investor like Goldman Sachs taking a position can be seen as a vote of confidence, potentially attracting other investors and stabilizing the stock price.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by suggesting stability and institutional backing.
Analyst Insight
A smart investor would view this as a positive signal, potentially indicating a stable long-term outlook for Ligand Pharmaceuticals, and might consider further research into the company's fundamentals.
Key Players & Entities
- Goldman Sachs Group Inc. (company) — filer of the SC 13G
- Ligand Pharmaceuticals Inc. (company) — subject company of the filing
- December 29, 2023 (date) — date of event requiring the filing
- $0.001 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- Other institutional investors may increase their positions in Ligand Pharmaceuticals Inc. following Goldman Sachs's disclosure. (Ligand Pharmaceuticals Inc.) — medium confidence, target: Q2 2024
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically designated under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Who is the subject company of this SC 13G filing?
The subject company is LIGAND PHARMACEUTICALS INCORPORATED, with a Central Index Key (CIK) of 0000886163.
Who filed this SC 13G statement?
The filing was made by GOLDMAN SACHS GROUP INC, with a Central Index Key (CIK) of 0000886982.
What is the CUSIP number for the class of securities mentioned in the filing?
The CUSIP number for the Common Stock, par value $0.001 per share, is 53220K504.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 29, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 12, 2024 regarding LIGAND PHARMACEUTICALS INC (LGNZZ).